Skip to main content

Table 1 Patient baseline characteristics

From: Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study

  Placebo (N = 31) Rebamipide 2% (N = 31) Rebamipide 4% (N = 32)
Male (%) 25 (81) 26 (84) 26 (81)
Age (mean ± SD) (%) 60 ± 9 61 ± 12 62 ± 9
ECOG PS (PS = 0) (%) 28 (90) 28 (90) 28 (88)
Primary site
 Oral cavity (%) 2 (6) 4 (13) 4 (13)
 Nasopharynx (%) 6 (19) 7 (23) 6 (19)
 Oropharynx (%) 17 (55) 14 (45) 15 (47)
 Hypopharynx (%) 5 (16) 6 (19) 6 (19)
 Larynx (%) 1 (3) 0 1 (3)
Prior surgery for head and neck cancer (with prior surgery) (%) 7 (23) 7 (23) 6 (19)
TNM staging of primary tumor
 T1 6 (19) 9 (29) 4 (13)
 T2 14 (45) 10 (32) 15 (47)
 T3 7 (23) 4 (13) 5 (16)
 T4 4 (13) 8 (26) 8 (25)
 N0 7 (23) 3 (10) 3 (9)
 N1 8 (26) 3 (10) 8 (25)
 N2 13 (42) 23 (74) 20 (63)
 N3 3 (10) 2 (6) 1 (3)
Radiation technique
 3D–CRT 4 (13) 9 (29) 7 (22)
 IMRT 27 (87) 22 (71) 25 (78)
  1. Data are presented as number and percent [n (%)]
  2. SD standard deviation, ECOG PS Eastern Cooperative Oncology Group performance status, 3D–CRT three-dimensional conformal radiation therapy, IMRT Intensity-Modulated Radiation Therapy